Related references
Note: Only part of the references are listed.Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities
Yazhuo Zhang et al.
MOLECULAR CANCER (2018)
Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions
Emanuela Felley-Bosco
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Quantitative Tyrosine Phosphoproteomics of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-treated Lung Adenocarcinoma Cells Reveals Potential Novel Biomarkers of Therapeutic Response
Xu Zhang et al.
MOLECULAR & CELLULAR PROTEOMICS (2017)
Inhibiting receptor tyrosine kinase AXL with small molecule inhibitor BMS-777607 reduces glioblastoma growth, migration, and invasion in vitro and in vivo
Julia Onken et al.
ONCOTARGET (2016)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
P. Baas et al.
ANNALS OF ONCOLOGY (2015)
Design and synthesis of close analogs of LCRF-0004, a potent and selective RON receptor tyrosine kinase inhibitor
Stephane L. Raeppel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Design and synthesis of constrained analogs of LCRF-0004 as potent RON tyrosine kinase inhibitors
Stephane L. Raeppel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Design, synthesis and RON receptor tyrosine kinase inhibitory activity of new head groups analogs of LCRF-0004
Franck Raeppel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini et al.
EMBO REPORTS (2015)
Roles of c-Met and RON Kinases in tumor progression and their potential as therapeutic targets
Katherine Chang et al.
ONCOTARGET (2015)
Discontinued in 2013: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
PROGgeneV2: enhancements on the existing database
Chirayu Pankaj Goswami et al.
BMC CANCER (2014)
Multipoint targeting of the PI3K/mTOR pathway in mesothelioma
S. Zhou et al.
BRITISH JOURNAL OF CANCER (2014)
Dramatic Antitumor Effects of the Dual MET/RON Small-Molecule Inhibitor LY2801653 in Non-Small Cell Lung Cancer
Ichiro Kawada et al.
CANCER RESEARCH (2014)
Tyrosine Phosphoproteomics Identifies Both Codrivers and Cotargeting Strategies for T790M-Related EGFR-TKI Resistance in Non-Small Cell Lung Cancer
Takeshi Yoshida et al.
CLINICAL CANCER RESEARCH (2014)
The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor
Kenichi Suda et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
Genetic modifiers of EGFR dependence in non-small cell lung cancer
Tanaz Sharifnia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Autocrine CSF-1R signaling drives mesothelioma chemoresistance via AKT activation
M. Cioce et al.
CELL DEATH & DISEASE (2014)
The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering MBD4-Dependent DNA Methylation Reprogramming
Stephanie Cunha et al.
CELL REPORTS (2014)
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
D. J. Pinato et al.
BRITISH JOURNAL OF CANCER (2013)
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan et al.
INVESTIGATIONAL NEW DRUGS (2013)
Ron Knockdown and Ron Monoclonal Antibody IMC-RON8 Sensitize Pancreatic Cancer to Histone Deacetylase Inhibitors (HDACi)
Yi Zou et al.
PLOS ONE (2013)
Biology of the TAM Receptors
Greg Lemke
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
Alejandro Vazquez-Martin et al.
SCIENTIFIC REPORTS (2013)
Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines
S. Zhao et al.
ONCOGENESIS (2013)
MSP-RON signalling in cancer: pathogenesis and therapeutic potential
Hang-Ping Yao et al.
NATURE REVIEWS CANCER (2013)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
Yao Dai et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Plasma Cell Membrane Localization of c-MET Predicts Longer Survival in Patients with Malignant Mesothelioma A Series of 157 Cases from the MESOPATH Group
Guenaelle Levallet et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Spatial regulation of receptor tyrosine kinases in development and cancer
Jessica B. Casaletto et al.
NATURE REVIEWS CANCER (2012)
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma
Daniel V. T. Catenacci et al.
CANCER BIOLOGY & THERAPY (2011)
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction
Silvia Benvenuti et al.
CANCER RESEARCH (2011)
IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration
Dawn V. Jaquish et al.
CARCINOGENESIS (2011)
Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
Davide Torti et al.
EMBO MOLECULAR MEDICINE (2011)
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park et al.
ENVIRONMENTAL HEALTH PERSPECTIVES (2011)
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
Marie Brevet et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells
Hang-Ping Yao et al.
MOLECULAR CANCER (2011)
AXL regulates mesothelioma proliferation and invasiveness
W-B Ou et al.
ONCOGENE (2011)
Validation of tissue microarray technology in malignant pleural mesothelioma
Steven C. H. Kao et al.
PATHOLOGY (2011)
Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma
Junji Nagahama et al.
PATHOLOGY RESEARCH AND PRACTICE (2011)
Identification of a novel series of potent RON receptor tyrosine kinase inhibitors
Stephane Raeppel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Projection of mesothelioma mortality in Britain using Bayesian methods
E. Tan et al.
BRITISH JOURNAL OF CANCER (2010)
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma
Alexandra Schramm et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2010)
RON and Cisplatin Resistance in Ovarian Cancer Cell Lines
Silvia Prislei et al.
ONCOLOGY RESEARCH (2010)
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells
Koji Kawaguchi et al.
CARCINOGENESIS (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles
Daniel R. Rhodes et al.
NEOPLASIA (2007)
EGFR expression: Associations with outcome and clinicopathological variables in malignant pleural mesothelioma
J. G. Edwards et al.
LUNG CANCER (2006)
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
R Jagadeeswaran et al.
CANCER RESEARCH (2006)
Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene
C Ghigna et al.
MOLECULAR CELL (2005)
The global burden of-disease due to occupational carcinogens
T Driscoll et al.
AMERICAN JOURNAL OF INDUSTRIAL MEDICINE (2005)
A five-amino-acid peptide blocks Met- and Ron-dependent cell migration
A Matzke et al.
CANCER RESEARCH (2005)
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling
GJ Gordon et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
Truncated RON tyrosine kinase drives tumor cell progression and abrogates cell-cell adhesion through E-cadherin transcriptional repression
C Bardella et al.
CANCER RESEARCH (2004)
Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor
BE Peace et al.
EXPERIMENTAL CELL RESEARCH (2003)
Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase
MH Wang et al.
CARCINOGENESIS (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Cross-talk between the proto-oncogenes Met and Ron
A Follenzi et al.
ONCOGENE (2000)
Share Paper
